Jakob Passweg

Active 1996–2025

250
Papers
34,115
Citations
101
h-index
235
i10-index

Citations

Citations per year for Jakob Passweg1983: 5 citations1985: 1 citations1997: 3 citations1998: 15 citations1999: 30 citations2000: 56 citations2001: 45 citations2002: 76 citations2003: 91 citations2004: 63 citations2005: 126 citations2006: 169 citations2007: 190 citations2008: 174 citations2009: 200 citations2010: 168 citations2011: 209 citations2012: 207 citations2013: 194 citations2014: 206 citations2015: 278 citations2016: 184 citations2017: 248 citations2018: 201 citations2019: 929 citations2020: 949 citations2021: 863 citations2022: 753 citations2023: 493 citations2024: 1,051 citations2025: 355 citations2026: 5 citations1984: no citations, so this year is not shown1986–1996: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,795 citing papers, 21.6% of this breakdownGermany: 1,078 citing papers, 8.3% of this breakdownItaly: 925 citing papers, 7.1% of this breakdownUnited Kingdom: 884 citing papers, 6.8% of this breakdownFrance: 868 citing papers, 6.7% of this breakdownChina: 605 citing papers, 4.7% of this breakdownSwitzerland: 547 citing papers, 4.2% of this breakdownNetherlands: 512 citing papers, 3.9% of this breakdownSpain: 502 citing papers, 3.9% of this breakdownCanada: 312 citing papers, 2.4% of this breakdownAustralia: 280 citing papers, 2.2% of this breakdownJapan: 280 citing papers, 2.2% of this breakdown
0%21.6%Other 26%

Fields

  • Medicine83.7%
  • Immunology and Microbiology9.3%
  • Biochemistry, Genetics and Molecular Biology5.5%
  • Engineering0.2%
  • Neuroscience0.2%
  • Agricultural and Biological Sciences0.1%
  • Other1%

Topics

  • Hematopoietic Stem Cell Transplantation11.9%
  • Acute Myeloid Leukemia Research9%
  • Myeloproliferative Neoplasms: Diagnosis and Treatment6.1%
  • Immune Cell Function and Interaction4.2%
  • Acute Lymphoblastic Leukemia research3.4%
  • Chronic Myeloid Leukemia Treatments3.1%
  • Other62.3%

Coauthors

All papers

Open in search
  1. A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders

    Authors: , , , , , , , , - New England Journal of Medicine 2005 cited by 3,459

  2. Molecular Minimal Residual Disease in Acute Myeloid Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 cited by 781

  3. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2019 cited by 393

  4. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Haematology 2020 cited by 538

  5. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years

    Authors: , , , , , , , , , , , , , , , , - Bone Marrow Transplantation 2021 cited by 428

  6. Burden and Timeline of Infectious Diseases in the First Year After Solid Organ Transplantation in the Swiss Transplant Cohort Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sabina De Geest, Olivier de Rougemont, Michael Dickenmann, Michel Duchosal, Laure Elkrief, Thomas Fehr, Sylvie Ferrari‐Lacraz, Christian Garzoni, Paola Gasche Soccal, Christophe Gaudet, Emiliano Giostra, Déla Golshayan, Karine Hadaya, Jörg Halter, D. Hauri, Dominik Heim, Christoph Hess, Sven Hillinger, Hans H. Hirsch, Günther Hofbauer, Uyen Huynh-Do, Franz Immer, Richard Klaghofer, Michael Koller, Bettina Laesser, Guido F. Laube, Roger Lehmann, Christian Lovis, Pietro Majno, Oriol Manuel, Hans‐Peter Marti, Pierre Yves Martin, Michele Martinelli, Pascal Meylan, Nicolas J Mueller, Antonia Müller, Thomas Müller, Beat Müllhaupt, Manuel Pascual, Jakob Passweg, Klara M. Posfay‐Barbe, Juliane Rick, Eddy Roosnek, Anne Rosselet, Silvia Rothlin, Frank Ruschitzka, Urs Schanz, Stefan Schaub, Aurelia Schnyder, Christian Seiler, Jan Sprachta, Susanne Stampf, Jürg Steiger, Guido Stirnimann, Christian Toso, Christian van Delden, Jean-Pierre Venetz, Jean Villard, Madeleine Wick, Markus J. Wilhelm, Patrick Yerly, Patrizia Amico, John‐David Aubert, Vanessa Banz, Guido Beldi, Christian Benden, Christoph Berger, Isabelle Binet, Pierre-Yves Bochud, Sanda Branca and 65 more - Clinical Infectious Diseases 2019 cited by 305

  7. Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Serena Marotta, Talha Munir, Jennifer M.L. Tjon, Suzanne Tavitian, Aline Praire, Laurence Clément, Florence Rabian, Luana Marano, Anita Hill, Elena Palmisani, Petra Muus, Fabiana Cacace, Camilla Frieri, M. Van Lint, Jakob Passweg, Judith Marsh, Gèrard Socié, Ghulam J. Mufti, Carlo Dufour, Antonio M. Risitano - New England Journal of Medicine 2022 cited by 298

  8. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation

    Authors: , , , , , , , , , , , , , , , , , , , , , , - The Lancet Haematology 2024 cited by 222

  9. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2017 cited by 376

  10. High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jennita Slomp, Alexander N. Snel, Marie‐Christiane Vekemans, Bob Löwenberg, Gert J. Ossenkoppele, Gerrit Jan Schuurhuis - Journal of Clinical Oncology 2013 cited by 449

  11. Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marie Robin, Raffaella Greco, Donal P. McLornan - Blood Advances 2024 cited by 61

  12. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mats Brune, Alexandros Spyridonidis, A Schmitt-Gräff, Walter J. F. M. van der Velden, Gerwin Huls, Stephan Mielke, Goetz Ulrich Grigoleit, Jürgen Kuball, Ryan Flynn, Gabriele Ihorst, Jing Du, Bruce R. Blazar, R. Arnold, Nicolaus Kröger, Jakob Passweg, Jörg Halter, G. Socié, Dietrich W. Beelen, Christian Peschel, Andreas Neubauer, Jürgen Finke, Justus Duyster, Nikolas von Bubnoff - Leukemia 2015 cited by 540

  13. Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey

    Authors: , , , , , , , , , , , , , , - Bone Marrow Transplantation 2023 cited by 85

  14. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors.

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nina Worel, Mickey B C Koh, Mahmoud Aljurf, Hildegard Greinix, Yoshiko Atsuta, Wael Saber - Haematologica 2021 cited by 237

  15. Dasatinib for treatment of CAR T-cell therapy-related complications

    Authors: , , , , , , , , - Journal for ImmunoTherapy of Cancer 2022 cited by 46

  16. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation

    Authors: , , , , , , , , , , , , , , , - Blood 2019 cited by 175

  17. Prospective Study of Polyomavirus Type BK Replication and Nephropathy in Renal-Transplant Recipients

    Authors: , , , , , , - New England Journal of Medicine 2002 cited by 1,214

  18. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation

    Authors: , , , , , , , , , , , , , , , , , , - Bone Marrow Transplantation 2011 cited by 322

  19. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marie-Cecile J. C. Legdeur, Thomas Fischer, Juergen Kuball, Jan J. Cornelissen, Kimmo Porkka, Gunnar Juliusson, Peter Meyer, Martin Höglund, Bjørn Tore Gjertsen, Jeroen J. W. M. Janssen, Gerwin Huls, Jakob Passweg, Jacqueline Cloos, Peter J.M. Valk, Catharina Van Elssen, Markus G. Manz, Yngvar Fløisand, Gert J. Ossenkoppele - Blood Advances 2021 cited by 66

  20. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms

    Authors: , , , , , , , , , , , , - Blood 2014 cited by 641

  21. IBMTR Severity INDEX FOR GRADING ACUTE GRAFT‐VERSUS‐HOST DISEASE: RETROSPECTIVE COMPARISON WITH GLUCKSBERG GRADE

    Authors: , , , , , , , , , , , , , - British Journal of Haematology 1997 cited by 691

  22. Solid Cancers after Bone Marrow Transplantation

    Authors: , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 1997 cited by 968

  23. Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2019 cited by 126

  24. Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey

    Authors: , , , , , , , , , , , , , , , , - Bone Marrow Transplantation 2022 cited by 72